Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1429 to 1433 of 1433 entries
Sorted by: Best Match Show Resources per page
Isolation and characterization of hESC-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles.

Cardiovascular research

Pezhouman A, Engel JL, Nguyen NB, Skelton RJP, Gilmore WB, Qiao R, Sahoo D, Zhao P, Elliott DA, Ardehali R.
PMID: 33744937
Cardiovasc Res. 2021 Mar 21; doi: 10.1093/cvr/cvab102. Epub 2021 Mar 21.

AIMS: We prospectively isolate and characterize first and second heart field- and nodal-like cardiomyocytes using a double reporter line from human embryonic stem cells. Our double reporter line utilizes two important transcription factors in cardiac development, TBX5 and NKX2-5....

Cite
Pezhouman A, Engel JL, Nguyen NB, et al. Isolation and characterization of hESC-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles. Cardiovasc Res. 2021;doi: 10.1093/cvr/cvab102.
Pezhouman, A., Engel, J. L., Nguyen, N. B., Skelton, R. J. P., Gilmore, W. B., Qiao, R., Sahoo, D., Zhao, P., Elliott, D. A., & Ardehali, R. (2021). Isolation and characterization of hESC-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles. Cardiovascular research, . https://doi.org/10.1093/cvr/cvab102
Pezhouman, Arash, et al. "Isolation and characterization of hESC-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles." Cardiovascular research vol. (2021). doi: https://doi.org/10.1093/cvr/cvab102
Pezhouman A, Engel JL, Nguyen NB, Skelton RJP, Gilmore WB, Qiao R, Sahoo D, Zhao P, Elliott DA, Ardehali R. Isolation and characterization of hESC-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles. Cardiovasc Res. 2021 Mar 21; doi: 10.1093/cvr/cvab102. Epub 2021 Mar 21. PMID: 33744937.
Copy Download .nbib Format: NLM
Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical .

Antimicrobial agents and chemotherapy

Su H, Zhu M, Tsui CK, van der Lee H, Tehupeiory-Kooreman M, Zoll J, Engel T, Li L, Zhu J, Lu Z, Zhang Q, Verweij PE, Deng S.
PMID: 33685896
Antimicrob Agents Chemother. 2021 Mar 08; doi: 10.1128/AAC.02546-20. Epub 2021 Mar 08.

Triazole resistance in

Cite
Su H, Zhu M, Tsui CK, et al. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical . Antimicrob Agents Chemother. 2021;doi: 10.1128/AAC.02546-20.
Su, H., Zhu, M., Tsui, C. K., van der Lee, H., Tehupeiory-Kooreman, M., Zoll, J., Engel, T., Li, L., Zhu, J., Lu, Z., Zhang, Q., Verweij, P. E., & Deng, S. (2021). Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical . Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.02546-20
Su, Huilin, et al. "Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical ." Antimicrobial agents and chemotherapy vol. (2021). doi: https://doi.org/10.1128/AAC.02546-20
Su H, Zhu M, Tsui CK, van der Lee H, Tehupeiory-Kooreman M, Zoll J, Engel T, Li L, Zhu J, Lu Z, Zhang Q, Verweij PE, Deng S. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical . Antimicrob Agents Chemother. 2021 Mar 08; doi: 10.1128/AAC.02546-20. Epub 2021 Mar 08. PMID: 33685896; PMCID: PMC8092882.
Copy Download .nbib Format: NLM
Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015.

European archives of psychiatry and clinical neuroscience

Glocker C, Grohmann R, Engel R, Seifert J, Bleich S, Stübner S, Toto S, Schüle C.
PMID: 33768297
Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1425-1435. doi: 10.1007/s00406-021-01241-3. Epub 2021 Mar 25.

Galactorrhea is a well-known adverse drug reaction (ADR) of numerous antipsychotic drugs (APD) and is often distressing for those affected. Methodological problems in the existing literature make it difficult to determine the prevalence of symptomatic hyperprolactinemia in persons treated...

Cite
Glocker C, Grohmann R, Engel R, et al. Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. Eur Arch Psychiatry Clin Neurosci. 2021;271(8):1425-1435doi: 10.1007/s00406-021-01241-3.
Glocker, C., Grohmann, R., Engel, R., Seifert, J., Bleich, S., Stübner, S., Toto, S., & Schüle, C. (2021). Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. European archives of psychiatry and clinical neuroscience, 271(8), 1425-1435. https://doi.org/10.1007/s00406-021-01241-3
Glocker, C, et al. "Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015." European archives of psychiatry and clinical neuroscience vol. 271,8 (2021): 1425-1435. doi: https://doi.org/10.1007/s00406-021-01241-3
Glocker C, Grohmann R, Engel R, Seifert J, Bleich S, Stübner S, Toto S, Schüle C. Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015. Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1425-1435. doi: 10.1007/s00406-021-01241-3. Epub 2021 Mar 25. PMID: 33768297; PMCID: PMC8563638.
Copy Download .nbib Format: NLM
Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.

EBioMedicine

Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G, Molina MJ, Vidal M, Barrios D, Mitchell RA, Jiménez A, Castellana C, Hernández-Luis P, Rodó P, Méndez S, Llupià A, Puyol L, Rodrigo Melero N, Carolis C, Mayor A, Izquierdo L, Varela P, Trilla A, Vilella A, Barroso S, Angulo A, Engel P, Tortajada M, García-Basteiro AL, Dobaño C.
PMID: 35032961
EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Epub 2022 Jan 11.

BACKGROUND: Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what...

Cite
Moncunill G, Aguilar R, Ribes M, et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022;75:103805doi: 10.1016/j.ebiom.2021.103805.
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., Jiménez, A., Castellana, C., Hernández-Luis, P., Rodó, P., Méndez, S., Llupià, A., Puyol, L., Rodrigo Melero, N., Carolis, C., Mayor, A., Izquierdo, L., Varela, P., Trilla, A., Vilella, A., Barroso, S., Angulo, A., Engel, P., Tortajada, M., García-Basteiro, A. L., & Dobaño, C. (2022). Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine, 75103805. https://doi.org/10.1016/j.ebiom.2021.103805
Moncunill, Gemma, et al. "Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers." EBioMedicine vol. 75 (2022): 103805. doi: https://doi.org/10.1016/j.ebiom.2021.103805
Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G, Molina MJ, Vidal M, Barrios D, Mitchell RA, Jiménez A, Castellana C, Hernández-Luis P, Rodó P, Méndez S, Llupià A, Puyol L, Rodrigo Melero N, Carolis C, Mayor A, Izquierdo L, Varela P, Trilla A, Vilella A, Barroso S, Angulo A, Engel P, Tortajada M, García-Basteiro AL, Dobaño C. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Epub 2022 Jan 11. PMID: 35032961.
Copy Download .nbib Format: NLM
HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021).

EClinicalMedicine

McGuire M, de Waal A, Karellis A, Janssen R, Engel N, Sampath R, Carmona S, Zwerling AA, Suarez MF, Pai NP.
PMID: 34430835
EClinicalMedicine. 2021 Aug 13;39:101059. doi: 10.1016/j.eclinm.2021.101059. eCollection 2021 Sep.

BACKGROUND: HIV self-testing (HIVST) is recommended by the WHO as an innovative strategy to reach UNAIDS targets to end HIV by 2030. HIVST with digital supports is defined as the use of digital interventions (e.g., website-based, social media, mobile...

Cite
McGuire M, de Waal A, Karellis A, et al. HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine. 2021;39:101059doi: 10.1016/j.eclinm.2021.101059.
McGuire, M., de Waal, A., Karellis, A., Janssen, R., Engel, N., Sampath, R., Carmona, S., Zwerling, A. A., Suarez, M. F., & Pai, N. P. (2021). HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine, 39101059. https://doi.org/10.1016/j.eclinm.2021.101059
McGuire, Madison, et al. "HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021)." EClinicalMedicine vol. 39 (2021): 101059. doi: https://doi.org/10.1016/j.eclinm.2021.101059
McGuire M, de Waal A, Karellis A, Janssen R, Engel N, Sampath R, Carmona S, Zwerling AA, Suarez MF, Pai NP. HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine. 2021 Aug 13;39:101059. doi: 10.1016/j.eclinm.2021.101059. eCollection 2021 Sep. PMID: 34430835; PMCID: PMC8367787.
Copy Download .nbib Format: NLM
Showing 1429 to 1433 of 1433 entries